NTLA Q2 2019 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+44.8% YoY

Gross Profit

-$14M-129.0% margin

Operating Income

-$27M-247.0% margin

Net Income

-$26M-231.0% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+6.6%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$352M

Total Liabilities

$76M

Stockholders' Equity

$277M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$8M	+44.8%
Gross Profit	-$14M	-$16M	+9.2%
Operating Income	-$27M	-$24M	-16.4%
Net Income	-$26M	-$22M	-15.6%